Company intelligence / Profile preview
Pharmaclon
Russiapharmaclon.ru ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Pharmaclon is a Russian biotech/pharma company with multiple approved biosimilar and recombinant protein therapeutics targeting immune system diseases, neoplasms, infectious diseases, and more. Its portfolio includes biosimilars for interferon alfa‑2b and gamma as well as recombinant TNF modulators. Several products are approved in Russia for indications such as multiple sclerosis, acute lymphoblastic leukemia, warts, chlamydia infections, and neoplasms. No detailed clinical results are publicly available.
- Therapeutic areas
- DermatologyNeurologyOncologyInfectious Diseases
- Modalities
- Recombinant proteinBiosimilarSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Pharmaclon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmaclon.